Even though Arvinas and Pfizer appear to have "written off" the drug, in one analyst's view, Rigel believes it can drive adoption among community-treated patients lacking SERD access.

At the ASCGT meeting, scientists reported that Carvykti-treated cells overexpressed the enzyme Granzyme K, which may be ...

T therapy Aucatzyl could usher in profitability by 2028, CEO Christian Itin said, but growth from other disease areas will ...

The firm said the epidermolysis bullosa cell therapy brought in $8.7 million in Q1 and that it will develop a prostate cancer cell therapy and deprioritize internal ophthalmology programs.

The firm will use the funding to advance therapies for gastroesophageal, liver, and HER2-positive tumors and conduct preclinical studies of an autoimmune candidate.

ETX101 reduced seizures and improved neurodevelopmental outcomes, but its impact was unexpectedly attenuated by using the ...

Attendees at a fireside chat at the ASGCT annual meeting noted disconnects between the agency's stated goal of speeding gene therapies to market and its actions.

The latest decision makes these treatments routinely available after having been accessible only through a managed access scheme.

Regeneron's Otarmeni was recently FDA approved for patients with OTOF-related hearing loss based on CHORD trial results.

The former commissioner pushed a regulatory pathway for rare disease drugs and launched a voucher program for expedited ...

The firm will report more data on the CAR T-cell therapy's durable efficacy later in the year and anticipates completing regulatory submissions in the fourth quarter.